Austrade invites Australian companies with capabilities across biotechnology clinical trials, drug discovery digital health and medtech/medical devices to participate in our upcoming delegation to BioAsia 2026 in Hyderabad from 16-18 February 2026.
India is a global life sciences leader supplying 60% of the world’s vaccines, leading in generics, and rapidly advancing in biopharma, med-tech, digital health, and clinical research. With world-class talent and cutting-edge innovation, India is shaping the future of global health.
India’s life sciences and healthcare sector is one of the world’s fastest-growing powered by strong manufacturing, deep scientific talent, and next-gen innovation in biologics, biosimilars, med-tech, and digital health.
India also presents a compelling opportunity for Australian clinical trials providers across Phases I-IV, particularly in oncology, metabolic diseases, vaccines, rare diseases, and digital health-enabled trials. Driven by its large genetically diverse patient population, India is rapidly expanding its network of accredited hospitals and research sites and increasing the adoption of global GCP and ICH standards, and IV, particularly in oncology, metabolic diseases, vaccines, rare diseases, and digital health–enabled trials. India presents a compelling opportunity for Australian CROs, site networks, eClinical vendors, monitors, lab/biomarkers services to build long term partnerships to offer hybrid trial models or expand their geographic reach for international biotech firms. Australia offers Indian biopharma and medtech companies a highly trusted, regulatory led trial environment with fast start-up timelines, world-class investigators and strong global data acceptability, making it an ideal for first in-human, early-phase, and global-registration studies.
Why you should participate
BioAsia 2026 - the premier life sciences and health-tech event hosted by the Telangana government - will bring together international leaders across the life sciences sector. This year's theme of "TechBio Unleashed: AI, Automation & the Biology Revolution" signifies the dedication to pioneering transformative innovations, cultivating strategic global partnerships, and accelerating the adoption of cutting-edge technologies that are redefining the future of healthcare delivery on a global scale.
BioAsia 2026 will also focus on the TechBio inflection point where the fusion of biology and technology is redefining how to understand, diagnose, and treat disease.
Hyderabad continues to lead with its innovation ecosystem, world-class infrastructure and strong collaborative spirit, bringing together biotechnology excellence and digital capability where biology meets AI.
Australian life sciences and healthcare service providers, medical device and pharma manufacturers, and digital health companies will have the opportunity to raise their profile through an international platform, and build partnerships and connections to unlock new export markets and increase export sales.
Companies across the following segments are encouraged to apply:
- biotechnology/biopharmaceuticals
- medical devices/medtech
- digital health.
Austrade’s business program will feature tailored business meetings, market briefings, and a networking event in the lead up to, and during the event. Austrade will work with all the Australian state governments to support outstanding Australian health businesses to diversify and grow their exports.
Australian Clinical Trials Initiative (ACTI)
The Austrade mission to CTFA 2026 is delivered as part of the broader Australian Clinical Trials Initiative (ACTI) ecosystem. ACTI is a coordinated, national effort to promote Australia as an attractive clinical trials destination. ACTI will encompass 25 events over 18 months, taking place across Europe, North America, the Middle East and Africa (MENA), and Asia-Pacific (APAC).
Go to the ACTI homepage to learn more.
Please register your interest in attending BioAsia 2026. Austrade will evaluate all registrations submitted and we will reach out to you to confirm your eligibility, as well as provide information on the next steps and confirmation of participation.
